The association between overexpression of HSF1 and poor prognosis in breast cancer is linked with Lapatinib (HER2 and EGFR inhibitor) (Yallowitz et al, 2018) and Trastuzumab (HER2 antibody) (Zhao et al, 2011) resistance. This evidence concerns the gene ERBB2 and breast carcinoma.